A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity
← catalyst calendarNCT07725809 · readout in 147 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
57estimated
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-23 | estimated | When the study began enrolling |
| Primary completion | 2027-01-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-13 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
- Healthy
Intervention
- Drug: PF-08653945
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Curve (AUC) of PF-08653945
measured Up to 57 days post-dose
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of PF-08653945
measured Up to 57 days post-dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed